A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan

BACKGROUND: Tocilizumab, an IL-6 receptor antagonist, was suggested as a possible treatment of severe or critical COVID-19 pneumonia in a small Chinese study. The TOCIVID-19 trial evaluates efficacy and tolerability of tocilizumab in the treatment of patients with severe or critical COVID-19 pneumon...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiodini, Paolo, Arenare, Laura, Piccirillo, Maria Carmela, Perrone, Francesco, Gallo, Ciro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538865/
https://www.ncbi.nlm.nih.gov/pubmed/33043164
http://dx.doi.org/10.1016/j.conctc.2020.100665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538865/
https://www.ncbi.nlm.nih.gov/pubmed/33043164
http://dx.doi.org/10.1016/j.conctc.2020.100665

Ejemplares similares